


Status: Currently Official on 14-Feb-2025
Official Date: Official as of 01-Jun-2022
Document Type: USP Monographs
DocId: GUID-84BE0137-6D63-4D65-9A39-150647DA7687_6_en-US
DOI: https://doi.org/10.31003/USPNF_M28340_06_01
DOI Ref: 3f27b

© 2025 USPC
Do not distribute

Doxycycline Hyclate

Change to read:



(C₂₂H₂₄N₂O₈ · HCl)₂ · C₂H₆O · H₂O ▲1025.88▲ (ERR 1-Jun-2022)
2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, monohydrochloride, compound with ethanol (2:1), monohydrate, [4S-(4α,4aα,5α,5aα,6α,12aα)]-;
(4S,4aR,5S,5aR,6R,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide monohydrochloride, compound with ethyl alcohol (2:1), monohydrate CAS RN®: 24390-14-5; UNII: 19XTS3T51U.

DEFINITION

Doxycycline Hyclate has a potency equivalent to NLT 800 µg/mg and NMT 920 µg/mg of doxycycline (C₂₂H₂₄N₂O₈).

IDENTIFICATION

- **A.** [SPECTROSCOPIC IDENTIFICATION TESTS \(197\)](#), [Infrared Spectroscopy](#): 197A or 197K
- **B.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the *Assay*.
- **C.** [IDENTIFICATION TESTS—GENERAL \(191\)](#), [Chemical Identification Tests, Chloride](#): Meets the requirements

ASSAY

PROCEDURE

Protect solutions containing doxycycline from light.

Solution A: Transfer 3.1 g of [monobasic potassium phosphate](#) and 0.5 g of [edetate disodium](#) to a 1000-mL volumetric flask. Add about 850 mL of [water](#) and 0.5 mL of [triethylamine](#), and mix. Dilute with [water](#) to volume and adjust with [1 N sodium hydroxide](#) to a pH of 8.5 ± 0.1.

Solution B: [Methanol](#)

Mobile phase: See [Table 1](#).

Table 1

Time (min)	Solution A (%)	Solution B (%)
0	90	10
2.0	90	10
6.0	85	15
8.0	60	40
8.1	90	10
10.0	90	10

Diluent: [0.01 N hydrochloric acid](#)

Standard solution: 0.1 mg/mL of [USP Doxycycline Hyclate RS](#) in *Diluent*. Sonicate as needed to dissolve.

Sample solution: 0.1 mg/mL of Doxycycline Hyclate in *Diluent*. Sonicate as needed to dissolve.

Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

Mode: LC

Detector: UV 270 nm

Column: 2.1-mm × 5-cm; 1.7-μm packing [L7](#)

Column temperature: 60°

Flow rate: 0.6 mL/min

Injection volume: 5 μL

System suitability

Sample: *Standard solution*

Suitability requirements

Tailing factor: NMT 1.5

Relative standard deviation: NMT 1.0%

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the quantity of doxycycline ($C_{22}H_{24}N_2O_8$), in μg/mg, in the portion of Doxycycline Hyclate taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times P$$

r_U = peak response from the *Sample solution*

r_S = peak response from the *Standard solution*

C_S = concentration of [USP Doxycycline Hyclate RS](#) in the *Standard solution* (mg/mL)

C_U = concentration of Doxycycline Hyclate in the *Sample solution* (mg/mL)

P = potency of doxycycline in [USP Doxycycline Hyclate RS](#) (μg/mg)

Acceptance criteria: 800–920 μg/mg

IMPURITIES

Change to read:

• ORGANIC IMPURITIES

Mobile phase, Diluent, and Chromatographic system: Proceed as directed in the Assay.

System suitability stock solution 1: 1 mg/mL each of [USP Methacycline Hydrochloride RS](#) and [USP Doxycycline Related Compound A RS](#) in *Diluent*

System suitability stock solution 2: 1.2 mg/mL of [USP Doxycycline Hyclate RS](#) in *Diluent*

System suitability solution: Transfer 5 mL of *System suitability stock solution 2* to a 25-mL volumetric flask, heat on a steam bath for 60 min, and evaporate to dryness on a hot plate, taking care not to char the residue. Dissolve the residue in *Diluent*, add 0.5 mL of *System suitability stock solution 1*, and dilute with *Diluent* to volume. Pass the solution through a suitable filter and use the filtrate. This solution contains a mixture of 4-epidoxycycline, methacycline, doxycycline related compound A, and doxycycline. When stored in a refrigerator, this solution may be used for 14 days.

Sensitivity solution: 0.001 mg/mL of [USP Doxycycline Hyclate RS](#) in *Diluent*

Standard solution: 0.002 mg/mL each of [USP Doxycycline Hyclate RS](#) and [USP Methacycline Hydrochloride RS](#) in *Diluent*

Sample solution: 2 mg/mL of Doxycycline Hyclate in *Diluent*. Sonicate as needed to dissolve.

System suitability

Samples: *System suitability solution*, *Sensitivity solution*, and *Standard solution*

Suitability requirements

Resolution: NLT 1.5 between methacycline and 4-epidoxycycline; NLT 1.5 between 4-epidoxycycline and doxycycline related compound A; NLT 2.0 between doxycycline related compound A and doxycycline, *System suitability solution*

Relative standard deviation: NMT 5.0% each for the doxycycline and methacycline peaks, *Standard solution*

Signal-to-noise ratio: NLT 10, *Sensitivity solution*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of methacycline in the portion of Doxycycline Hyclate taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times P \times F \times 100$$

r_U = peak response of methacycline from the *Sample solution*

r_S = peak response of methacycline from the *Standard solution*

C_S = concentration of [USP Methacycline Hydrochloride RS](#) in the *Standard solution* (mg/mL)

C_U = concentration of Doxycycline Hyclate in the *Sample solution* (mg/mL)

P = potency of methacycline in [USP Methacycline Hydrochloride RS](#) (μg/mL)

F = conversion factor, 0.001 mg/ μ g

Calculate the percentage of 4-epidoxycycline, doxycycline related compound A, doxycycline related compound F, and any individual unspecified impurity in the portion of Doxycycline Hyclate taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times P \times (F_1/F_2) \times 100$$

r_U = peak response of each impurity from the *Sample solution*

r_S = peak response of doxycycline from the *Standard solution*

C_S = concentration of [USP Doxycycline Hyclate RS](#) in the *Standard solution* (mg/mL)

C_U = concentration of Doxycycline Hyclate in the *Sample solution* (mg/mL)

P = potency of doxycycline in [USP Doxycycline Hyclate RS](#) (μ g/mg)

F_1 = conversion factor, 0.001 mg/ μ g

F_2 = relative response factor (see [Table 2](#))

Acceptance criteria: See [Table 2](#). The reporting threshold is 0.05%.

Table 2

Name	Relative Retention Time	Relative Response Factor	Acceptance Criteria, NMT (%)
Methacycline	0.51	1.0	2.0
4-Epidoxycycline ^a	0.62	1.0	0.5
Doxycycline related compound A (6-epidoxycycline)	0.72	0.60	2.0
Doxycycline	1.0	—	—
Doxycycline related compound F ^b	1.20	0.61	1.0
Any individual unspecified impurity	—	1.0	0.10
Total impurities	—	—	2.5

^a (4R,4aR,5S,5aR,6R,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide. Main degradation product.

^{▲b} (4S,4aR,5S,5aR,6R,12aS)-2-Acetyl-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-4a,5a,6,12a-tetrahydrotetracene-1,11(4H,5H)-dione. ▲ (ERR 1-Jun-2022)

• CONTENT OF ETHANOL

Diluent: [Dimethylacetamide](#)

Standard solution: 2.5 mg/mL of [ethanol](#) in *Diluent*

Sample solution: 50 mg/mL of Doxycycline Hyclate in *Diluent* prepared as follows. Transfer 100 mg of Doxycycline Hyclate to a 10-mL flask, fitted with a septum, add 2 mL of *Diluent*, and vortex to dissolve.

Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

Mode: GC

Detector: Flame ionization

Columns

Guard: 1-m deactivated silica

Analytical: 0.32-mm \times 30-m fused silica; coated with a 1.0- μ m film of phase [G25](#)

Temperatures

Injection port: 150°

Detector: 250°

Table 3

Initial Temperature (°)	Temperature Ramp (°/min)	Final Temperature (°)	Hold Time at Final Temperature (min)
45	—	45	2
45	15	100	—
100	40	240	5

Carrier gas: Helium
Flow rate: 5 mL/min
Injection volume: 1 µL
Injection type: Split; split ratio 6:1
Run time: NLT 2.2 times the retention time of ethanol

System suitability

Sample: *Standard solution*
Suitability requirements
Tailing factor: NMT 2.2
Relative standard deviation: NMT 10%

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of ethanol in the portion of Doxycycline Hyclate taken:

Result = $(r_U/r_S) \times (C_S/C_U) \times 100$

r_U = peak response of ethanol from the *Sample solution*

r_S = peak response of ethanol from the *Standard solution*

C_S = concentration of ethanol in the *Standard solution* (mg/mL)

C_U = concentration of Doxycycline Hyclate in the *Sample solution* (mg/mL)

Acceptance criteria: 4.3%–5.5%; for veterinary products, 4.3%–6.0%

SPECIFIC TESTS

- **CRYSTALLINITY (695):** Meets the requirements
- **pH (791):**
Sample solution: Nominally 10 mg/mL of doxycycline from Doxycycline Hyclate
Acceptance criteria: 2.0–3.0
- **WATER DETERMINATION (921), Method I:** 1.4%–2.8%
- **STERILITY TESTS (71):** Where the label states that Doxycycline Hyclate is sterile, it meets the requirements. If the membrane filtration test is used, use *Fluid D* instead of *Fluid A*.
- **BACTERIAL ENDOTOXINS TEST (85):** Where the label states that Doxycycline Hyclate is sterile or must be subjected to further processing during the preparation of injectable dosage forms, it has NMT 1.14 USP Endotoxin Units/mg of doxycycline.


ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in tight containers, protected from light.
- **LABELING:** Where it is intended for use in preparing injectable dosage forms, the label states that it is sterile or must be subjected to further processing during the preparation of injectable dosage forms.


Change to read:

- **USP REFERENCE STANDARDS (11):**
[USP Doxycycline Hyclate RS](#)
[USP Doxycycline Related Compound A RS](#)

[NOTE—May be available as a free base or a hydrochloride salt.]
(4S,4aR,5S,5aR,6S,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide.



(4S,4aR,5S,5aR,6S,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide, monohydrochloride.



[USP Methacycline Hydrochloride RS](#)

(4S,4aR,5S,5aR,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-2-naphthacenecarboxamide hydrochloride.

C₂₂H₂₂N₂O₈ · HCl 478.88

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
DOXYCYCLINE HYCLATE	Documentary Standards Support	SM12020 Small Molecules 1

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. 46(3)

Current DocID: GUID-84BE0137-6D63-4D65-9A39-150647DA7687_6_en-US

DOI: https://doi.org/10.31003/USPNF_M28340_06_01

DOI ref: [3f27b](#)

OFFICIAL